0.71
+0.1046(+17.29%)
Currency In USD
Address
840 Memorial Drive
Cambridge, MA 02139
United States of America
Phone
617 498 0020
Website
Sector
Healthcare
Industry
Biotechnology
Employees
123
First IPO Date
June 28, 2017
| Name | Title | Pay | Year Born |
| Dr. Martin H. Huber M.D. | President, Chief Executive Officer & Director | 780,460 | 1961 |
| Mr. Mohan Bala Ph.D. | Senior Vice President & Chief Development Officer | 549,430 | 1965 |
| Ms. Alejandra Veronica Carvajal J.D. | Senior Vice President, Secretary & Chief Legal Officer | 558,117 | 1974 |
| Mr. Brian C. DeSchuytner | Senior Vice President, Chief Financial Officer & Chief Operating Officer | 567,039 | 1978 |
| Dr. Timothy B. Lowinger Ph.D. | Senior Vice President and Chief Science & Technology Officer | 587,528 | 1964 |
| Mr. Ashish Mandelia | Chief Accounting Officer | 0 | 1975 |
| Mr. Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Dr. Marc Damelin Ph.D. | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. | 0 | N/A |
| Mr. Chuck Miller | Senior Vice President of Regulatory Affairs | 0 | N/A |
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.